Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

Nanni Schmitt, Jana-Julia Siegler, Lena Wagner, Nicole Schulze, Alexandra Beck, Wolf-Karsten Hofmann, Torsten Haneke, Uwe Reusch, José Medina-Echeverz, Jan Endell, Thorsten Ross, Christian Merz, Daniel Nowak

Blood (2022) 140 (Supplement 1): 8815–8816.

https://doi.org/10.1182/blood-2022-169729

Published: 2022

Journal Articles

AFM28, a Novel Bispecific Innate Cell Engager (ICE ® ), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Jana-Julia Götz, Jens Pahl, Nanni Schmitt, Thomas Müller, Torsten Haneke, Izabela Kozlowska, Séverine Sarlang, Stefan Knackmuss, Eike Peters, Uwe Reusch, Thorsten Ross, Daniel Nowak, Wolf-Karsten Hofmann, Christian Merz

Blood (2021) 138 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2021-152463

Published: 2021

Journal Articles

Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies

Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, Ute Schniegler-Mattox, Jens Pahl, Michael Tesar, Joachim Koch

Blood (2021) 138 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2021-150552

Published: 2021

Journal Articles

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross, PhD, Uwe Reusch, PhD, Susanne Wingert, PhD, Torsten Haneke, PhD, Katja Klausz, PhD, Anna-Kathrin Otte, PhD, Natalie Schub, MD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Thomas Valerius, MD, Martin Gramatzki, MD, Matthias Peipp, PhD, Michael Tesar, PhD, Erich Rajkovic, PhD MBA, Martin Treder, PhD

Blood (2018) 132 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2018-99-118970

Published: 2018

Journal Articles

CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages

Susanne Wingert, PhD, Uwe Reusch, PhD, Armin Beez, Jens Pahl, PhD, Adelheid Cerwenka, PhD, Joachim Koch, PhD, Martin Treder, PhD

Blood (2018) 132 (Supplement 1): 1111.

https://doi.org/10.1182/blood-2018-99-118427

Published: 2018

Journal Articles

AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma

Thorsten Gantke, PhD, Uwe Reusch, PhD, Christian Kellner, PhD, Katja Klausz, PhD, Torsten Haneke, PhD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Anne Kerber, MD, Matthias Peipp, PhD, Martin Treder, PhD

Blood (2017) 130 (Supplement 1): 3082.

https://doi.org/10.1182/blood.V130.Suppl_1.3082.3082

Published: 2017

Journal Articles

Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb ® AFM11

Johannes Duell, MD, Dragana Slavkovic, PhD, Margarete Karg, Uwe Reusch, PhD, Florian Eisele, Jens-Peter Marschner, MD, Hermann Einsele, MD, Martin Treder, PhD, Max S. Topp, MD

Blood (2016) 128 (22): 4130.

https://doi.org/10.1182/blood.V128.22.4130.4130

Published: 2016

Journal Articles

Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma

Thorsten Gantke, PhD, Michael Weichel, PhD, Uwe Reusch, PhD, Kristina Ellwanger, PhD, Ivica Fucek, Remko Griep, PhD, Vera Molkenthin, PhD, Oscar Kashala, MD PhD DSc, Martin Treder, PhD

Blood (2016) 128 (22): 4513.

https://doi.org/10.1182/blood.V128.22.4513.4513

Published: 2016

Journal Articles

AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation

Jens Pahl, PhD, Uwe Reusch, PhD, Thorsten Gantke, PhD, Anne Kerber, MD, Joachim Koch, PhD, Martin Treder, PhD, Adelheid Cerwenka, PhD

Blood (2016) 128 (22): 1764.

https://doi.org/10.1182/blood.V128.22.1764.1764

Published: 2016

Journal Articles

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

Xing Zhao, Narendiran Rajasekaran, PhD, Uwe Reusch, PhD, Jens-Peter Marschner, MD, Martin Treder, Holbrook Kohrt, MD

Blood (2015) 126 (23): 2747.

https://doi.org/10.1182/blood.V126.23.2747.2747

Published: 2015

Journal Articles

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

Xing Zhao, Narendiran Rajasekaran, PhD, Uwe Reusch, PhD, Michael Weichel, Kristina Ellwanger, Jens-Peter Marschner, MD, Martin Treder, Holbrook Kohrt, MD

Blood (2015) 126 (23): 2763.

https://doi.org/10.1182/blood.V126.23.2763.2763

Published: 2015

Journal Articles

A CD19/CD3 Bispecific Tandab, AFM11, Recruits T Cells To Potently and Safely Kill CD19 + Tumor Cells

Eugene Zhukovsky, PhD, Uwe Reusch, Carmen Burkhardt, Stefan Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, Kristina Ellwanger, Melvyn Little, PhD

Blood (2013) 122 (21): 4405.

https://doi.org/10.1182/blood.V122.21.4405.4405

Published: 2013

Journal Articles

A T Cell-Engaging CD3 Recruit-Tandab Potently Kills CD19 + Tumor B Cells

Eugene Zhukovsky, PhD, Uwe Reusch, Carmen Burkhardt, Stefan Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, Kristina Ellwanger

Blood (2012) 120 (21): 3721.

https://doi.org/10.1182/blood.V120.21.3721.3721

Published: 2012

Journal Articles

Activation of T- and NK- Cells through CD19xCD3 and CD19xCD16A Bispecific TandAb Antibodies in Patients with B-Cell Non-Hodgkin's Lymphoma.

Lisa Poertner, Markus Uhrberg, Kathrin Schoenberg, Daniela Bruennert, Uwe Reusch, Melvin Little, Rainer Haas, Frank Neumann

Blood (2009) 114 (22): 1950.

https://doi.org/10.1182/blood.V114.22.1950.1950

Published: 2009

NARROW

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

AFM28, a Novel Bispecific Innate Cell Engager (ICE ® ), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages

AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma

Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb ® AFM11

Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma

AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

A CD19/CD3 Bispecific Tandab, AFM11, Recruits T Cells To Potently and Safely Kill CD19 + Tumor Cells

A T Cell-Engaging CD3 Recruit-Tandab Potently Kills CD19 + Tumor B Cells

Activation of T- and NK- Cells through CD19xCD3 and CD19xCD16A Bispecific TandAb Antibodies in Patients with B-Cell Non-Hodgkin's Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only